nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—ALB—focal segmental glomerulosclerosis	0.416	1	CbGaD
Naproxen—SLCO1A2—Cyclosporine—focal segmental glomerulosclerosis	0.181	0.438	CbGbCtD
Naproxen—SLC22A6—Cyclosporine—focal segmental glomerulosclerosis	0.11	0.266	CbGbCtD
Naproxen—CYP2C8—Cyclosporine—focal segmental glomerulosclerosis	0.0723	0.175	CbGbCtD
Naproxen—CYP2C9—Cyclosporine—focal segmental glomerulosclerosis	0.0505	0.122	CbGbCtD
Naproxen—Tendon disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00425	0.0294	CcSEcCtD
Naproxen—Carcinoma—Cyclosporine—focal segmental glomerulosclerosis	0.00367	0.0254	CcSEcCtD
Naproxen—Papilloedema—Cyclosporine—focal segmental glomerulosclerosis	0.00349	0.0241	CcSEcCtD
Naproxen—PTGS2—nephron—focal segmental glomerulosclerosis	0.00329	0.155	CbGeAlD
Naproxen—Renal tubular necrosis—Cyclosporine—focal segmental glomerulosclerosis	0.0031	0.0214	CcSEcCtD
Naproxen—Pyelonephritis—Cyclosporine—focal segmental glomerulosclerosis	0.00292	0.0202	CcSEcCtD
Naproxen—Stomach ache—Cyclosporine—focal segmental glomerulosclerosis	0.00261	0.018	CcSEcCtD
Naproxen—Nephropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00233	0.0161	CcSEcCtD
Naproxen—AKR1C3—nephron tubule—focal segmental glomerulosclerosis	0.0021	0.0991	CbGeAlD
Naproxen—SLC22A6—nephron tubule—focal segmental glomerulosclerosis	0.00209	0.0987	CbGeAlD
Naproxen—Ear disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00205	0.0142	CcSEcCtD
Naproxen—UGT2B7—kidney—focal segmental glomerulosclerosis	0.002	0.0945	CbGeAlD
Naproxen—Urine abnormality—Cyclosporine—focal segmental glomerulosclerosis	0.002	0.0138	CcSEcCtD
Naproxen—Gastric ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00191	0.0132	CcSEcCtD
Naproxen—Cerebration impaired—Cyclosporine—focal segmental glomerulosclerosis	0.00188	0.013	CcSEcCtD
Naproxen—Urine analysis abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00188	0.013	CcSEcCtD
Naproxen—Serum creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.0018	0.0125	CcSEcCtD
Naproxen—Optic neuritis—Cyclosporine—focal segmental glomerulosclerosis	0.0018	0.0125	CcSEcCtD
Naproxen—AKR1C3—cortex of kidney—focal segmental glomerulosclerosis	0.0018	0.0849	CbGeAlD
Naproxen—SLC22A6—cortex of kidney—focal segmental glomerulosclerosis	0.00179	0.0845	CbGeAlD
Naproxen—Tooth disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00171	0.0118	CcSEcCtD
Naproxen—Nail disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00171	0.0118	CcSEcCtD
Naproxen—UGT1A1—kidney—focal segmental glomerulosclerosis	0.0017	0.0803	CbGeAlD
Naproxen—Peptic ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00166	0.0115	CcSEcCtD
Naproxen—Menstrual disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00163	0.0112	CcSEcCtD
Naproxen—PTGS1—endothelium—focal segmental glomerulosclerosis	0.00162	0.0766	CbGeAlD
Naproxen—Influenza-like symptoms—Cyclosporine—focal segmental glomerulosclerosis	0.00155	0.0107	CcSEcCtD
Naproxen—PTGS2—endothelium—focal segmental glomerulosclerosis	0.00155	0.0732	CbGeAlD
Naproxen—Herpes zoster—Cyclosporine—focal segmental glomerulosclerosis	0.00147	0.0102	CcSEcCtD
Naproxen—Cholestasis—Cyclosporine—focal segmental glomerulosclerosis	0.00146	0.0101	CcSEcCtD
Naproxen—Skin ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00142	0.00984	CcSEcCtD
Naproxen—Abscess—Cyclosporine—focal segmental glomerulosclerosis	0.0014	0.00968	CcSEcCtD
Naproxen—Acne—Cyclosporine—focal segmental glomerulosclerosis	0.00132	0.0091	CcSEcCtD
Naproxen—Neoplasm malignant—Cyclosporine—focal segmental glomerulosclerosis	0.0013	0.00897	CcSEcCtD
Naproxen—Disturbance in attention—Cyclosporine—focal segmental glomerulosclerosis	0.00128	0.00884	CcSEcCtD
Naproxen—Musculoskeletal stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.00124	0.00854	CcSEcCtD
Naproxen—Rectal haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00123	0.00848	CcSEcCtD
Naproxen—Arthropathy—Cyclosporine—focal segmental glomerulosclerosis	0.00122	0.00842	CcSEcCtD
Naproxen—Cellulitis—Cyclosporine—focal segmental glomerulosclerosis	0.00122	0.00842	CcSEcCtD
Naproxen—Herpes simplex—Cyclosporine—focal segmental glomerulosclerosis	0.0012	0.00831	CcSEcCtD
Naproxen—Glossitis—Cyclosporine—focal segmental glomerulosclerosis	0.0012	0.00831	CcSEcCtD
Naproxen—Hyperuricaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00119	0.00826	CcSEcCtD
Naproxen—Nocturia—Cyclosporine—focal segmental glomerulosclerosis	0.00119	0.00826	CcSEcCtD
Naproxen—Hearing impaired—Cyclosporine—focal segmental glomerulosclerosis	0.00116	0.00805	CcSEcCtD
Naproxen—Cataract—Cyclosporine—focal segmental glomerulosclerosis	0.00116	0.00805	CcSEcCtD
Naproxen—SLCO1A2—kidney—focal segmental glomerulosclerosis	0.00115	0.0544	CbGeAlD
Naproxen—Blood uric acid increased—Cyclosporine—focal segmental glomerulosclerosis	0.00113	0.0078	CcSEcCtD
Naproxen—Hyperkalaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00109	0.00753	CcSEcCtD
Naproxen—Eructation—Cyclosporine—focal segmental glomerulosclerosis	0.00109	0.00753	CcSEcCtD
Naproxen—Influenza like illness—Cyclosporine—focal segmental glomerulosclerosis	0.00108	0.00744	CcSEcCtD
Naproxen—Urinary incontinence—Cyclosporine—focal segmental glomerulosclerosis	0.00107	0.0074	CcSEcCtD
Naproxen—Blood urea increased—Cyclosporine—focal segmental glomerulosclerosis	0.00105	0.00723	CcSEcCtD
Naproxen—Coma—Cyclosporine—focal segmental glomerulosclerosis	0.00101	0.007	CcSEcCtD
Naproxen—Oesophagitis—Cyclosporine—focal segmental glomerulosclerosis	0.00101	0.007	CcSEcCtD
Naproxen—Urine output increased—Cyclosporine—focal segmental glomerulosclerosis	0.001	0.00693	CcSEcCtD
Naproxen—Sepsis—Cyclosporine—focal segmental glomerulosclerosis	0.000962	0.00665	CcSEcCtD
Naproxen—Mental disability—Cyclosporine—focal segmental glomerulosclerosis	0.000962	0.00665	CcSEcCtD
Naproxen—Lymphadenopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000943	0.00652	CcSEcCtD
Naproxen—Diabetes mellitus—Cyclosporine—focal segmental glomerulosclerosis	0.000925	0.00639	CcSEcCtD
Naproxen—Polyuria—Cyclosporine—focal segmental glomerulosclerosis	0.000916	0.00633	CcSEcCtD
Naproxen—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.000908	0.00627	CcSEcCtD
Naproxen—Vascular purpura—Cyclosporine—focal segmental glomerulosclerosis	0.000899	0.00622	CcSEcCtD
Naproxen—Deafness—Cyclosporine—focal segmental glomerulosclerosis	0.000899	0.00622	CcSEcCtD
Naproxen—Disorientation—Cyclosporine—focal segmental glomerulosclerosis	0.000899	0.00622	CcSEcCtD
Naproxen—Eczema—Cyclosporine—focal segmental glomerulosclerosis	0.000895	0.00619	CcSEcCtD
Naproxen—Hepatic failure—Cyclosporine—focal segmental glomerulosclerosis	0.000895	0.00619	CcSEcCtD
Naproxen—Eye pain—Cyclosporine—focal segmental glomerulosclerosis	0.000891	0.00616	CcSEcCtD
Naproxen—Visual disturbance—Cyclosporine—focal segmental glomerulosclerosis	0.000849	0.00587	CcSEcCtD
Naproxen—Renal impairment—Cyclosporine—focal segmental glomerulosclerosis	0.000845	0.00584	CcSEcCtD
Naproxen—Dermatitis bullous—Cyclosporine—focal segmental glomerulosclerosis	0.000842	0.00582	CcSEcCtD
Naproxen—Purpura—Cyclosporine—focal segmental glomerulosclerosis	0.000835	0.00577	CcSEcCtD
Naproxen—Anaphylactoid reaction—Cyclosporine—focal segmental glomerulosclerosis	0.000831	0.00575	CcSEcCtD
Naproxen—Cardiac failure—Cyclosporine—focal segmental glomerulosclerosis	0.000824	0.0057	CcSEcCtD
Naproxen—Hypoglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000824	0.0057	CcSEcCtD
Naproxen—CYP2C8—kidney—focal segmental glomerulosclerosis	0.000806	0.038	CbGeAlD
Naproxen—Osteoarthritis—Cyclosporine—focal segmental glomerulosclerosis	0.000805	0.00556	CcSEcCtD
Naproxen—Affect lability—Cyclosporine—focal segmental glomerulosclerosis	0.000792	0.00547	CcSEcCtD
Naproxen—Migraine—Cyclosporine—focal segmental glomerulosclerosis	0.000792	0.00547	CcSEcCtD
Naproxen—Mood swings—Cyclosporine—focal segmental glomerulosclerosis	0.000762	0.00527	CcSEcCtD
Naproxen—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.000754	0.00521	CcSEcCtD
Naproxen—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.000737	0.0051	CcSEcCtD
Naproxen—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.000735	0.00508	CcSEcCtD
Naproxen—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000727	0.00503	CcSEcCtD
Naproxen—Cramp muscle—Cyclosporine—focal segmental glomerulosclerosis	0.000724	0.00501	CcSEcCtD
Naproxen—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.000712	0.00492	CcSEcCtD
Naproxen—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.00071	0.0049	CcSEcCtD
Naproxen—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.0007	0.00484	CcSEcCtD
Naproxen—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.000695	0.00481	CcSEcCtD
Naproxen—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000682	0.00471	CcSEcCtD
Naproxen—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.000669	0.00462	CcSEcCtD
Naproxen—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000667	0.00461	CcSEcCtD
Naproxen—PTGS1—kidney—focal segmental glomerulosclerosis	0.000653	0.0308	CbGeAlD
Naproxen—Dysuria—Cyclosporine—focal segmental glomerulosclerosis	0.00065	0.00449	CcSEcCtD
Naproxen—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.000642	0.00444	CcSEcCtD
Naproxen—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.000629	0.00435	CcSEcCtD
Naproxen—Hyperglycaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000627	0.00434	CcSEcCtD
Naproxen—PTGS2—kidney—focal segmental glomerulosclerosis	0.000625	0.0295	CbGeAlD
Naproxen—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.000624	0.00431	CcSEcCtD
Naproxen—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.000618	0.00427	CcSEcCtD
Naproxen—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.000611	0.00422	CcSEcCtD
Naproxen—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.000609	0.00421	CcSEcCtD
Naproxen—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.000608	0.0042	CcSEcCtD
Naproxen—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.000608	0.0042	CcSEcCtD
Naproxen—Jaundice—Cyclosporine—focal segmental glomerulosclerosis	0.000604	0.00418	CcSEcCtD
Naproxen—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000604	0.00418	CcSEcCtD
Naproxen—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.000603	0.00417	CcSEcCtD
Naproxen—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.000603	0.00417	CcSEcCtD
Naproxen—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.000591	0.00409	CcSEcCtD
Naproxen—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.000586	0.00405	CcSEcCtD
Naproxen—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.000585	0.00404	CcSEcCtD
Naproxen—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.000582	0.00402	CcSEcCtD
Naproxen—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.000559	0.00387	CcSEcCtD
Naproxen—Rhinitis—Cyclosporine—focal segmental glomerulosclerosis	0.000558	0.00386	CcSEcCtD
Naproxen—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.000557	0.00385	CcSEcCtD
Naproxen—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000557	0.00385	CcSEcCtD
Naproxen—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.000552	0.00382	CcSEcCtD
Naproxen—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00055	0.0038	CcSEcCtD
Naproxen—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000547	0.00378	CcSEcCtD
Naproxen—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000546	0.00377	CcSEcCtD
Naproxen—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.000536	0.00371	CcSEcCtD
Naproxen—Fenoprofen—ALB—focal segmental glomerulosclerosis	0.00053	0.281	CrCbGaD
Naproxen—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.000519	0.00359	CcSEcCtD
Naproxen—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000505	0.00349	CcSEcCtD
Naproxen—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000502	0.00347	CcSEcCtD
Naproxen—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.000499	0.00345	CcSEcCtD
Naproxen—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.000497	0.00344	CcSEcCtD
Naproxen—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.000492	0.0034	CcSEcCtD
Naproxen—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000488	0.00337	CcSEcCtD
Naproxen—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.000484	0.00335	CcSEcCtD
Naproxen—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.000477	0.0033	CcSEcCtD
Naproxen—Tension—Cyclosporine—focal segmental glomerulosclerosis	0.000475	0.00329	CcSEcCtD
Naproxen—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.000471	0.00325	CcSEcCtD
Naproxen—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.000466	0.00322	CcSEcCtD
Naproxen—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.000457	0.00316	CcSEcCtD
Naproxen—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.000454	0.00314	CcSEcCtD
Naproxen—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00045	0.00311	CcSEcCtD
Naproxen—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000448	0.0031	CcSEcCtD
Naproxen—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.000443	0.00306	CcSEcCtD
Naproxen—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.000437	0.00302	CcSEcCtD
Naproxen—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.000435	0.00301	CcSEcCtD
Naproxen—Leukopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000434	0.003	CcSEcCtD
Naproxen—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000423	0.00292	CcSEcCtD
Naproxen—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.00042	0.0029	CcSEcCtD
Naproxen—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.000418	0.00289	CcSEcCtD
Naproxen—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.000412	0.00285	CcSEcCtD
Naproxen—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000412	0.00285	CcSEcCtD
Naproxen—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000412	0.00285	CcSEcCtD
Naproxen—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.000411	0.00284	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00041	0.00283	CcSEcCtD
Naproxen—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000408	0.00282	CcSEcCtD
Naproxen—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.000403	0.00279	CcSEcCtD
Naproxen—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.000399	0.00276	CcSEcCtD
Naproxen—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.000395	0.00273	CcSEcCtD
Naproxen—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000395	0.00273	CcSEcCtD
Naproxen—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.000393	0.00272	CcSEcCtD
Naproxen—Indomethacin—ALB—focal segmental glomerulosclerosis	0.000391	0.207	CrCbGaD
Naproxen—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000388	0.00268	CcSEcCtD
Naproxen—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000387	0.00268	CcSEcCtD
Naproxen—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000384	0.00265	CcSEcCtD
Naproxen—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.000382	0.00264	CcSEcCtD
Naproxen—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.000377	0.00261	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00036	0.00249	CcSEcCtD
Naproxen—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.000358	0.00247	CcSEcCtD
Naproxen—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.000355	0.00245	CcSEcCtD
Naproxen—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000353	0.00244	CcSEcCtD
Naproxen—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.000352	0.00243	CcSEcCtD
Naproxen—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000348	0.00241	CcSEcCtD
Naproxen—Flurbiprofen—ALB—focal segmental glomerulosclerosis	0.000346	0.183	CrCbGaD
Naproxen—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000344	0.00238	CcSEcCtD
Naproxen—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000341	0.00236	CcSEcCtD
Naproxen—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.000341	0.00236	CcSEcCtD
Naproxen—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000338	0.00234	CcSEcCtD
Naproxen—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000338	0.00234	CcSEcCtD
Naproxen—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000326	0.00225	CcSEcCtD
Naproxen—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000323	0.00223	CcSEcCtD
Naproxen—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.000314	0.00217	CcSEcCtD
Naproxen—Ketoprofen—ALB—focal segmental glomerulosclerosis	0.000313	0.166	CrCbGaD
Naproxen—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.000313	0.00216	CcSEcCtD
Naproxen—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.000313	0.00216	CcSEcCtD
Naproxen—Ibuprofen—ALB—focal segmental glomerulosclerosis	0.000308	0.163	CrCbGaD
Naproxen—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000291	0.00201	CcSEcCtD
Naproxen—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000284	0.00196	CcSEcCtD
Naproxen—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.00028	0.00193	CcSEcCtD
Naproxen—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000271	0.00187	CcSEcCtD
Naproxen—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000261	0.00181	CcSEcCtD
Naproxen—ALB—Scavenging of heme from plasma—APOL1—focal segmental glomerulosclerosis	0.000261	0.114	CbGpPWpGaD
Naproxen—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000251	0.00174	CcSEcCtD
Naproxen—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000249	0.00172	CcSEcCtD
Naproxen—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000249	0.00172	CcSEcCtD
Naproxen—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000248	0.00171	CcSEcCtD
Naproxen—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000235	0.00162	CcSEcCtD
Naproxen—PTGS1—Overview of nanoparticle effects—COL4A1—focal segmental glomerulosclerosis	0.000154	0.0672	CbGpPWpGaD
Naproxen—PTGS2—Overview of nanoparticle effects—COL4A1—focal segmental glomerulosclerosis	0.000123	0.0534	CbGpPWpGaD
Naproxen—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOL1—focal segmental glomerulosclerosis	0.000104	0.0453	CbGpPWpGaD
Naproxen—SLCO1A2—Transport of organic anions—ALB—focal segmental glomerulosclerosis	8.06e-05	0.0351	CbGpPWpGaD
Naproxen—AKR1C3—Retinoid metabolism and transport—LPL—focal segmental glomerulosclerosis	7.49e-05	0.0326	CbGpPWpGaD
Naproxen—SLCO1A2—Recycling of bile acids and salts—ALB—focal segmental glomerulosclerosis	5.97e-05	0.026	CbGpPWpGaD
Naproxen—AKR1C3—Bile acid and bile salt metabolism—ALB—focal segmental glomerulosclerosis	5.46e-05	0.0238	CbGpPWpGaD
Naproxen—ALB—Binding and Uptake of Ligands by Scavenger Receptors—COL4A1—focal segmental glomerulosclerosis	5.36e-05	0.0233	CbGpPWpGaD
Naproxen—PTGS1—Overview of nanoparticle effects—FN1—focal segmental glomerulosclerosis	4.77e-05	0.0208	CbGpPWpGaD
Naproxen—ALB—Lipoprotein metabolism—LIPC—focal segmental glomerulosclerosis	4.41e-05	0.0192	CbGpPWpGaD
Naproxen—PTGS1—Prostaglandin Synthesis and Regulation—EDN1—focal segmental glomerulosclerosis	4.31e-05	0.0188	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—ACTN4—focal segmental glomerulosclerosis	4.07e-05	0.0177	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—ACTN4—focal segmental glomerulosclerosis	3.87e-05	0.0169	CbGpPWpGaD
Naproxen—AKR1C3—Diseases associated with visual transduction—LPL—focal segmental glomerulosclerosis	3.82e-05	0.0167	CbGpPWpGaD
Naproxen—PTGS2—Overview of nanoparticle effects—FN1—focal segmental glomerulosclerosis	3.79e-05	0.0165	CbGpPWpGaD
Naproxen—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—focal segmental glomerulosclerosis	3.48e-05	0.0151	CbGpPWpGaD
Naproxen—PTGS2—Prostaglandin Synthesis and Regulation—EDN1—focal segmental glomerulosclerosis	3.43e-05	0.0149	CbGpPWpGaD
Naproxen—SLCO1A2—Bile acid and bile salt metabolism—ALB—focal segmental glomerulosclerosis	3.12e-05	0.0136	CbGpPWpGaD
Naproxen—SLCO1A2—Transport of vitamins, nucleosides, and related molecules—ALB—focal segmental glomerulosclerosis	2.99e-05	0.013	CbGpPWpGaD
Naproxen—ALB—Lipid and lipoprotein metabolism—LIPC—focal segmental glomerulosclerosis	2.93e-05	0.0127	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—COL4A1—focal segmental glomerulosclerosis	2.84e-05	0.0124	CbGpPWpGaD
Naproxen—ALB—Lipoprotein metabolism—LPL—focal segmental glomerulosclerosis	2.69e-05	0.0117	CbGpPWpGaD
Naproxen—PTGS2—Aryl Hydrocarbon Receptor—LPL—focal segmental glomerulosclerosis	2.36e-05	0.0103	CbGpPWpGaD
Naproxen—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—focal segmental glomerulosclerosis	2.29e-05	0.00999	CbGpPWpGaD
Naproxen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—focal segmental glomerulosclerosis	2.25e-05	0.0098	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—PIAS1—focal segmental glomerulosclerosis	2.1e-05	0.00917	CbGpPWpGaD
Naproxen—CYP1A2—Melatonin metabolism and effects—EDN1—focal segmental glomerulosclerosis	1.99e-05	0.00867	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—ACTN4—focal segmental glomerulosclerosis	1.8e-05	0.00785	CbGpPWpGaD
Naproxen—ALB—Lipid and lipoprotein metabolism—LPL—focal segmental glomerulosclerosis	1.79e-05	0.00778	CbGpPWpGaD
Naproxen—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—focal segmental glomerulosclerosis	1.51e-05	0.0066	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	1.5e-05	0.00652	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—focal segmental glomerulosclerosis	1.39e-05	0.00605	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—LPL—focal segmental glomerulosclerosis	1.34e-05	0.00582	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	1.32e-05	0.00574	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—SERPINE1—focal segmental glomerulosclerosis	1.16e-05	0.00507	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—ALB—focal segmental glomerulosclerosis	1.16e-05	0.00506	CbGpPWpGaD
Naproxen—ALB—Vitamin B12 Metabolism—SERPINE1—focal segmental glomerulosclerosis	1.16e-05	0.00504	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—FN1—focal segmental glomerulosclerosis	9.7e-06	0.00422	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—COL4A4—focal segmental glomerulosclerosis	9.47e-06	0.00412	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—SERPINE1—focal segmental glomerulosclerosis	9.41e-06	0.0041	CbGpPWpGaD
Naproxen—ALB—Hemostasis—ACTN4—focal segmental glomerulosclerosis	9.3e-06	0.00405	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—SERPINE1—focal segmental glomerulosclerosis	9.24e-06	0.00402	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—FN1—focal segmental glomerulosclerosis	9.24e-06	0.00402	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—ALB—focal segmental glomerulosclerosis	9.22e-06	0.00402	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	9.13e-06	0.00398	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—COL4A1—focal segmental glomerulosclerosis	8.7e-06	0.00379	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—NOS2—focal segmental glomerulosclerosis	8.68e-06	0.00378	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—TRPC6—focal segmental glomerulosclerosis	8.65e-06	0.00377	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	8.56e-06	0.00373	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—SERPINE1—focal segmental glomerulosclerosis	8.07e-06	0.00351	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	7.9e-06	0.00344	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	7.81e-06	0.0034	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—SERPINE1—focal segmental glomerulosclerosis	7.69e-06	0.00335	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	7.54e-06	0.00328	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—SERPINE1—focal segmental glomerulosclerosis	7.48e-06	0.00326	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	7.43e-06	0.00323	CbGpPWpGaD
Naproxen—UGT2B7—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	7.4e-06	0.00322	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	7.35e-06	0.0032	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—GNAQ—focal segmental glomerulosclerosis	7.23e-06	0.00315	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—focal segmental glomerulosclerosis	7.03e-06	0.00306	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—LIPC—focal segmental glomerulosclerosis	6.67e-06	0.0029	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	6.52e-06	0.00284	CbGpPWpGaD
Naproxen—SLCO1A2—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	6.42e-06	0.0028	CbGpPWpGaD
Naproxen—ALB—Hemostasis—ANGPT2—focal segmental glomerulosclerosis	6.22e-06	0.00271	CbGpPWpGaD
Naproxen—SLC22A6—SLC-mediated transmembrane transport—ALB—focal segmental glomerulosclerosis	6.03e-06	0.00263	CbGpPWpGaD
Naproxen—UGT1A1—NRF2 pathway—TGFB1—focal segmental glomerulosclerosis	6.01e-06	0.00262	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	6e-06	0.00261	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—CTGF—focal segmental glomerulosclerosis	5.87e-06	0.00256	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	5.74e-06	0.0025	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—MMP9—focal segmental glomerulosclerosis	5.6e-06	0.00244	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—focal segmental glomerulosclerosis	5.55e-06	0.00242	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	5.41e-06	0.00236	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.41e-06	0.00235	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	5.38e-06	0.00234	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	5.23e-06	0.00228	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	5.17e-06	0.00225	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—TGFB1—focal segmental glomerulosclerosis	5.09e-06	0.00222	CbGpPWpGaD
Naproxen—AKR1C3—Disease—LPL—focal segmental glomerulosclerosis	4.86e-06	0.00212	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—focal segmental glomerulosclerosis	4.85e-06	0.00211	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—TGFB1—focal segmental glomerulosclerosis	4.61e-06	0.00201	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	4.55e-06	0.00198	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	4.52e-06	0.00197	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	4.47e-06	0.00195	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TRPC6—focal segmental glomerulosclerosis	4.46e-06	0.00194	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—LIPC—focal segmental glomerulosclerosis	4.38e-06	0.00191	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—FN1—focal segmental glomerulosclerosis	4.3e-06	0.00187	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	4.21e-06	0.00183	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	4.18e-06	0.00182	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	4.14e-06	0.0018	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—LPL—focal segmental glomerulosclerosis	4.07e-06	0.00177	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	3.98e-06	0.00173	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—TRPC6—focal segmental glomerulosclerosis	3.86e-06	0.00168	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—CTGF—focal segmental glomerulosclerosis	3.86e-06	0.00168	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—LIPC—focal segmental glomerulosclerosis	3.81e-06	0.00166	CbGpPWpGaD
Naproxen—AKR1C3—Disease—NOS2—focal segmental glomerulosclerosis	3.79e-06	0.00165	CbGpPWpGaD
Naproxen—ALB—Hemostasis—GNAQ—focal segmental glomerulosclerosis	3.73e-06	0.00162	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	3.71e-06	0.00161	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	3.68e-06	0.0016	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—SERPINE1—focal segmental glomerulosclerosis	3.58e-06	0.00156	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—LIPC—focal segmental glomerulosclerosis	3.56e-06	0.00155	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.55e-06	0.00155	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	3.51e-06	0.00153	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—AGT—focal segmental glomerulosclerosis	3.48e-06	0.00152	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	3.43e-06	0.00149	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	3.43e-06	0.00149	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—LPL—focal segmental glomerulosclerosis	3.4e-06	0.00148	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	3.4e-06	0.00148	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CTGF—focal segmental glomerulosclerosis	3.36e-06	0.00146	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	3.26e-06	0.00142	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	3.22e-06	0.0014	CbGpPWpGaD
Naproxen—AKR1C3—Disease—SERPINE1—focal segmental glomerulosclerosis	3.19e-06	0.00139	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	3.16e-06	0.00137	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	3.14e-06	0.00137	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CTGF—focal segmental glomerulosclerosis	3.13e-06	0.00136	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GNAQ—focal segmental glomerulosclerosis	3.09e-06	0.00135	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	3.07e-06	0.00134	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	3.02e-06	0.00131	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	2.93e-06	0.00127	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.91e-06	0.00127	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—LIPC—focal segmental glomerulosclerosis	2.9e-06	0.00126	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.89e-06	0.00126	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	2.7e-06	0.00118	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—FN1—focal segmental glomerulosclerosis	2.69e-06	0.00117	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—LPL—focal segmental glomerulosclerosis	2.67e-06	0.00116	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—ALB—focal segmental glomerulosclerosis	2.67e-06	0.00116	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	2.61e-06	0.00114	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	2.58e-06	0.00112	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	2.57e-06	0.00112	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CTGF—focal segmental glomerulosclerosis	2.55e-06	0.00111	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	2.55e-06	0.00111	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GNAQ—focal segmental glomerulosclerosis	2.35e-06	0.00102	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—LPL—focal segmental glomerulosclerosis	2.33e-06	0.00101	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—LIPC—focal segmental glomerulosclerosis	2.3e-06	0.001	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—AGT—focal segmental glomerulosclerosis	2.29e-06	0.000996	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—TGFB1—focal segmental glomerulosclerosis	2.26e-06	0.000984	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.24e-06	0.000974	CbGpPWpGaD
Naproxen—ALB—Hemostasis—FN1—focal segmental glomerulosclerosis	2.22e-06	0.000965	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	2.2e-06	0.000957	CbGpPWpGaD
Naproxen—ALB—Hemostasis—NOS2—focal segmental glomerulosclerosis	2.19e-06	0.000954	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	2.18e-06	0.000951	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—LPL—focal segmental glomerulosclerosis	2.17e-06	0.000946	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	2.09e-06	0.00091	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	2.07e-06	0.000902	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CTGF—focal segmental glomerulosclerosis	2.03e-06	0.000883	CbGpPWpGaD
Naproxen—AKR1C3—Disease—TGFB1—focal segmental glomerulosclerosis	2.02e-06	0.000878	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—AGT—focal segmental glomerulosclerosis	1.99e-06	0.000867	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—LIPC—focal segmental glomerulosclerosis	1.87e-06	0.000816	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.87e-06	0.000814	CbGpPWpGaD
Naproxen—ALB—Metabolism—LIPC—focal segmental glomerulosclerosis	1.86e-06	0.000811	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—AGT—focal segmental glomerulosclerosis	1.86e-06	0.000809	CbGpPWpGaD
Naproxen—ALB—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	1.84e-06	0.000803	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.79e-06	0.000779	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.79e-06	0.000778	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—LPL—focal segmental glomerulosclerosis	1.77e-06	0.000771	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—ALB—focal segmental glomerulosclerosis	1.75e-06	0.000764	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.71e-06	0.000746	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.69e-06	0.000734	CbGpPWpGaD
Naproxen—PTGS2—Disease—LPL—focal segmental glomerulosclerosis	1.68e-06	0.000731	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CTGF—focal segmental glomerulosclerosis	1.65e-06	0.000718	CbGpPWpGaD
Naproxen—ALB—Metabolism—CTGF—focal segmental glomerulosclerosis	1.64e-06	0.000714	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—ALB—focal segmental glomerulosclerosis	1.53e-06	0.000665	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.53e-06	0.000665	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—LIPC—focal segmental glomerulosclerosis	1.53e-06	0.000664	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.52e-06	0.000662	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—AGT—focal segmental glomerulosclerosis	1.51e-06	0.00066	CbGpPWpGaD
Naproxen—ALB—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.51e-06	0.000658	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—ALB—focal segmental glomerulosclerosis	1.43e-06	0.000621	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.41e-06	0.000615	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—LPL—focal segmental glomerulosclerosis	1.41e-06	0.000612	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.37e-06	0.000597	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CTGF—focal segmental glomerulosclerosis	1.34e-06	0.000585	CbGpPWpGaD
Naproxen—PTGS2—Disease—NOS2—focal segmental glomerulosclerosis	1.31e-06	0.000571	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—LIPC—focal segmental glomerulosclerosis	1.3e-06	0.000568	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.24e-06	0.000539	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—AGT—focal segmental glomerulosclerosis	1.2e-06	0.000524	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.17e-06	0.000511	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.16e-06	0.000507	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ALB—focal segmental glomerulosclerosis	1.16e-06	0.000506	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CTGF—focal segmental glomerulosclerosis	1.15e-06	0.0005	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—LPL—focal segmental glomerulosclerosis	1.14e-06	0.000498	CbGpPWpGaD
Naproxen—ALB—Metabolism—LPL—focal segmental glomerulosclerosis	1.14e-06	0.000495	CbGpPWpGaD
Naproxen—PTGS2—Disease—SERPINE1—focal segmental glomerulosclerosis	1.1e-06	0.000481	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.06e-06	0.00046	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—AGT—focal segmental glomerulosclerosis	9.78e-07	0.000426	CbGpPWpGaD
Naproxen—ALB—Metabolism—AGT—focal segmental glomerulosclerosis	9.73e-07	0.000424	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—LPL—focal segmental glomerulosclerosis	9.31e-07	0.000405	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ALB—focal segmental glomerulosclerosis	9.23e-07	0.000402	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—AGT—focal segmental glomerulosclerosis	7.96e-07	0.000347	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—LPL—focal segmental glomerulosclerosis	7.95e-07	0.000346	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ALB—focal segmental glomerulosclerosis	7.51e-07	0.000327	CbGpPWpGaD
Naproxen—PTGS2—Disease—TGFB1—focal segmental glomerulosclerosis	6.97e-07	0.000303	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—AGT—focal segmental glomerulosclerosis	6.81e-07	0.000296	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ALB—focal segmental glomerulosclerosis	6.11e-07	0.000266	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALB—focal segmental glomerulosclerosis	5.22e-07	0.000227	CbGpPWpGaD
